(Q53958979)

English

Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.

scientific article published in January 1998

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/9483167

Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/9483167

Parkinson's disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

C. David Marsden

8

object named as

C D Marsden

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

José Félix Martí Massó

6

object named as

J F Marti Masso

0 references

1

object named as

U K Rinne

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/9483167

author name string

F Bracco

2

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/9483167

C Chouza

3

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/9483167

E Dupont

4

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/9483167

O Gershanik

5

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/9483167

J F Marti Masso

6

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/9483167

J L Montastruc

7

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/9483167

publication date

1 January 1998

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/9483167

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/9483167

55 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/9483167

23-30

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/9483167

L-dopa treatment and Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term effects of bromocriptine given to de novo patients with idiopathic Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Motor response to apomorphine and levodopa in asymmetric Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autonomic nervous system dysfunction in Parkinson's disease: relationships with age, medication, duration, and severity

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lisuride, a dopamine agonist in the treatment of early Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cabergoline: a long-acting dopamine agonist in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of Parkinson's disease: Problems with a progressing disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/9483167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-199855001-00004

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 May 2018

http://europepmc.org/abstract/MED/9483167

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53958979&oldid=1560899280"